BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services


Soluplus® — the solid solution — is an innovative excipient that enables new levels of solubility and bioavailability for poorly soluble active ingredients. Developed specifically for solid solutions, this easy-to-process polymer produces a significant improvement in API release.

Thanks to its high flowability and excellent extrudability, Soluplus® exhibits superior performance in forming solid solutions, especially in hot-melt extrusion processes. These solid solutions make the active pharmaceutical ingredient available in a dissolved state, leading to improved bioavailability once in the body. As a result, the polymer is opening new doors in the research and development of innovative pharmaceuticals.

Soluplus® is not limited to solid solutions formed via hot-melt extrusion, but can also be used as a matrix former in spray-drying processes. In addition, it can be deployed as a binder in wet or dry granulation and in drug layering.

A wide range of toxicological studies have been performed on Soluplus®, and the safety of the product has been comprehensively documented.

BASF Pharma Ingredients and Services
www.soluplus.com
pharma-ingredients@basf.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here